Knight Therapeutics holds 19.85% of 60 Degrees Pharma

Knight Therapeutics Inc. filed a Schedule 13G reporting a passive ownership stake in 60 Degrees Pharmaceuticals, Inc. common stock.

Rhea-AI Filing Summary

Knight Therapeutics Inc. filed a Schedule 13G reporting a passive ownership stake in 60 Degrees Pharmaceuticals, Inc. common stock. As of July 22, 2026, Knight beneficially owns 658,629 shares of common stock, representing 19.85% of the class. This percentage is based on 2,659,288 shares outstanding as of May 15, 2026. Knight has sole voting power and sole dispositive power over all 658,629 shares, with no shared voting or dispositive power reported.

Key Figures

Shares beneficially owned: 658,629 shares Ownership percentage: 19.85% Shares outstanding: 2,659,288 shares +2 more

5 metrics

Shares beneficially owned 658,629 shares Common stock beneficially owned by Knight Therapeutics as of July 22, 2026

Ownership percentage 19.85% Percent of SXTP common stock class held by Knight Therapeutics

Shares outstanding 2,659,288 shares SXTP common stock outstanding as of May 15, 2026, used for percentage calculation

Sole voting power 658,629 shares Shares over which Knight has sole power to vote or direct the vote

Sole dispositive power 658,629 shares Shares over which Knight has sole power to dispose or direct disposition

Key Terms

Schedule 13G, beneficially owns, sole voting power, dispositive power, +1 more

5 terms

Schedule 13G regulatory

"Knight Therapeutics Inc. filed a Schedule 13G reporting a passive ownership stake"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

beneficially owns financial

"the Reporting Person beneficially owns 658,629 shares of common stock"

Beneficially owns means a person or entity enjoys the economic benefits and control of a security even if the legal title or registration is held in another name. Think of it like having the keys and profits from a car that is registered to a friend: you use it, benefit from it, and make decisions about it even though the official paperwork lists someone else. For investors, this matters because it reveals who truly controls shares, affects voting power, potential conflicts of interest, and regulatory disclosure obligations.

sole voting power financial

"Sole Voting Power 658,629.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole Dispositive Power 658,629.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

percent of class financial

"(b) | Percent of class: 19.85%. The above percentage is calculated"

Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in SXTP does Knight Therapeutics report on this Schedule 13G?

Knight Therapeutics reports beneficial ownership of 658,629 shares of 60 Degrees Pharmaceuticals (SXTP) common stock, representing 19.85% of the outstanding shares, based on 2,659,288 shares outstanding as of May 15, 2026.

How is the 19.85% ownership of SXTP by Knight Therapeutics calculated?

The 19.85% ownership is calculated using 2,659,288 SXTP shares outstanding as of May 15, 2026. Knight beneficially owns 658,629 shares, and this fraction of the total outstanding shares yields the reported ownership percentage.

Does Knight Therapeutics have sole or shared voting power over its SXTP shares?

Knight Therapeutics has sole voting power over 658,629 shares of SXTP common stock and no shared voting power. It also has sole dispositive power over the same number of shares, with no shared dispositive power reported.

What type of securities in SXTP are covered by Knight Therapeutics' Schedule 13G?

The Schedule 13G covers common stock, par value $0.0001 per share, of 60 Degrees Pharmaceuticals, Inc. Knight reports beneficial ownership and control rights over 658,629 shares of this common stock class.

As of what dates are Knight Therapeutics’ SXTP ownership figures reported?

Knight’s 658,629 SXTP shares are reported as beneficially owned as of July 22, 2026. The 2,659,288 outstanding shares used to calculate the 19.85% stake are stated as outstanding as of May 15, 2026.

What control does Knight Therapeutics have over the disposition of its SXTP shares?

Knight Therapeutics has sole dispositive power over 658,629 SXTP shares, meaning it alone can decide to sell or otherwise dispose of these shares. It reports no shared dispositive power with any other party.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2026 - 04:06 PM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

60 DEGREES PHARMACEUTICALS, INC.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

83006G104

(CUSIP Number)

07/22/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 83006G104

1

Names of Reporting Persons

Knight Therapeutics Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CANADA (FEDERAL LEVEL)

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 658,629.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 658,629.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

658,629.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

19.85 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) Based on 2,659,288 shares of common stock, par value $0.0001 per share, of 60 Degrees Pharmaceuticals, Inc. (the "Issuer") that are issued and outstanding as of May 15, 2026, as reported by the Issuer in its quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 15, 2026.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: 60 DEGREES PHARMACEUTICALS, INC.
(b)	Address of issuer's principal executive offices: 1025 Connecticut Avenue, NW Suite 1000, Washington D.C. 20036
Item 2.
(a)	Name of person filing: Knight Therapeutics Inc.
(b)	Address or principal business office or, if none, residence: 600 - 100 boul. Alexis Nihon Montreal, QC, H4M 2P2
(c)	Citizenship: Canada
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP Number(s): 83006G104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: As of July 22, 2026, the Reporting Person beneficially owns 658,629 shares of common stock, par value $0.0001 per share, of the Issuer.
(b)	Percent of class: 19.85%. The above percentage is calculated based on 2,659,288 shares of common stock, par value $0.0001 per share, of the Issuer that are issued and outstanding as of May 15, 2026, as reported by the Issuer in its quarterly report on Form 10-Q filed with the U.S. Securities and Exchange Commission on May 15, 2026.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 658,629 shares of common stock of the Issuer
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 658,629 shares of common stock of the Issuer
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Knight Therapeutics Inc.

Signature:	/s/ Samira Sakhia
Name/Title:	Samira Sakhia/President and Chief Executive Officer
Date:	07/28/2026